STRO-002-GM2: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (clinicaltrials.gov) - Jun 11, 2024 - P1 | N=58 | Active, not recruiting | Sponsor: Sutro Biopharma, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2024 ➔ Jan 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025
Combination therapy • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|